Long-term outcome of patients with jia treated with etanercept, results of the biologic register jumbo

Rheumatology (United Kingdom)

Volumn 51, Issue 8, 2012, Pages 1407-1415

  Minden, Kirsten ^a,b   Niewerth, Martina ^a   Zink, Angela ^a   Seipelt, Eva ^c   Foeldvari, Ivan ^d   Girschick, Hermann ^e   Ganser, Gerd ^f   Horneff, Gerd ^g  

^a Leibnitz Institute   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c HELIOS KLINIKUM BERLIN BUCH   (Germany)

^d Rheumatologikum Hamburg an der Schön Klinik Hamburg Eilbek   (Germany)

^e Deutsche Akademie fur Kinder und Jugendmedizin e V   (Germany)

^f Sankt Josef Stift Sendenhorst   (Germany)

^g Asklepios Kinderklinik St Augustin GmbH   (Germany)

Author keywords

Etanercept; Health related quality of life; Juvenile idiopathic arthritis; Long term outcome; Morbidity

Indexed keywords

ETANERCEPT;

ADULT; ARTICLE; COMORBIDITY; DISEASE COURSE; ENTERITIS; FATIGUE; FEMALE; FUNCTIONAL STATUS; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLYARTHRITIS; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; TREATMENT DURATION; UVEITIS;

ADOLESCENT; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865211612     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes019     Document Type: Article

References (45)

1. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology 2002;41:1428-35.
2. Flato B, Lien G, Smerdel A et al. Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol 2003;30:386-93.
3. Solari N, Viola S, Pistorio A et al. Assessing current outcomes of juvenile idiopathic arthritis: a cross-sectional study in a tertiary center sample. Arthritis Rheum 2008;59: 1571-9.
4. Ringold S, Seidel KD, Koepsell TD et al. Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations. Rheumatology 2009;48:972-7.
5. Papsdorf V, Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology 2011;50: 214-21.
6. Wallace CA, Huang B, Bandeira M et al. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005;52:3554-62.
7. Foell D, Wulffraat N, Wedderburn LR et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010;303: 1266-73.
8. Horneff G, Schmeling H, Biedermann T et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1638-44.
9. Petty RE, Southwood TR, Manners P et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
10. Zink A, Listing J, Kary S et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005;64:1274-9.
11. Bruce B, Fries JF. The Stanford health assessment questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003;30:167-78.
12. Ware JE, Snow KK, Kosinski M et al. SF-36 health survey manual and interpretation guide. Boston, MA: New England Medical Center, The Health Institute, 1993.
13. Wallace CA, Ruperto N, Giannini E et al. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4.
14. Magni-Manzoni S, Ruperto N, Pistorio A et al. Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum 2008;59:1120-7.
15. International Conference on Harmonisation. Clinical safety data management: definitions and standards for expedited reporting. www.emea.eu.int/pdfs/human/ich/037795en.pdfCPMP/ICH/377/95 (25 January 2010, date last accessed).
16. Woodworth TG, Furst DE, Strand V et al. Standardizing assessment of adverse effects in rheumatology clinical trials: status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies. J Rheumatol 2001;28:1163-9.
17. Public Use File. National Health Survey 1998. Berlin: Robert-Koch-Institute, 1998.
18. Foster HE, Marshall N, Myers A et al. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum 2003;48:767-75.
19. Horneff G, De Bock F, Foeldvari I et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68: 519-25.
20. Southwood TR, Foster HE, Davidson JE et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology 2011;50:189-95.
21. Lovell DJ, Reiff A, Ilowite NT et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504.
22. Prince FH, Twilt M, ten Cate R et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009;68:635-41.
23. TynjäläP, Vähäsalo P, Honkanen V et al. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis. Ann Rheum Dis 2009; 68:552-7.
24. Oen K, Malleson PN, Cabral DA et al. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002;29:1989-99.
25. Kirwan JR, Minnock P, Adebajo A et al. Patient perspective: fatigue as a recommended patient-centred outcome measure in rheumatoid arthritis. J Rheumatol 2007;34: 1174-7.
26. Ostile IL, Johansson I, Aasland A et al. Self-rated physical and psychosocial health in a cohort of young adults with juvenile idiopathic arthritis. Scand J Rheumatol 2010;39: 318-25.
27. Peterson LS, Mason T, Nelson AM et al. Psychological outcomes and health status of adults who have had juvenile rheumatoid arthritis: a controlled, population-based study. Arthritis Rheum 1997;40: 2235-40.
28. Zak M, Pedersen FK. Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatology 2000; 39:198-204.
29. Savolainen HA, Isomaki HA. Decrease in the number of deaths from secondary amyloidosis in patients with juvenile rheumatoid arthritis. J Rheumatol 1993;20: 1201-3.
30. Albers HM, Wessels JA, van der Straaten RJ et al. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum 2009;61:46-51.
31. van Rossum MA, van Soesbergen RM, Boers M et al. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis 2007;66: 1518-24.
32. Magnani A, Pistorio A, Magni-Manzoni S et al. Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. J Rheumatol 2009;36:628-34.
33. Minden K, Niewerth M. Paediatric rheumatologic database - analysis after 10 years. Arthritis + Rheuma 2011;1:57-8.
34. Lovell DJ, Reiff A, Jones OY et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006;54: 1987-94.
35. Giannini EH, Ilowite NT, Lovell DJ et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009;60:2794-804.
36. Wang F, Wang NS. Etanercept therapy-associated acute uveitis: a case report and literature review. Clin Exp Rheumatol 2009;27:838-9.
37. Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? Observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res 2010;35: 751-6.
38. Fouache D, Goëb V, Massy-Guillemant N et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology 2009;48:761-4.
39. Wiegering V, Morbach H, Dick A et al. Crohn's disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature. Rheumatol Int 2010;30:801-4.
40. van Dijken TD, Vastert SJ, Gerloni VM et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 2011;38:1441-6.
41. Ozgocmen S, Ardicoglu O, Kamanli A et al. Pattern of disease onset, diagnostic delay, and clinical features in juvenile onset and adult onset ankylosing spondylitis. J Rheumatol 2009;36:2830-3.
42. Bremander A, Petersson IF, Bergman S et al. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res 2011;63:550-6.
43. Public Use File GSTel03. The Telephone Health Survey 2003. Berlin: Robert Koch Institute, 2006.
44. Han C, Robinson DW, Hackett MV et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33: 2167-72.
45. Maradit-Kremers H, Nicola PJ, Crowson CS et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722-32.